Characteristic | Women, n = 200 at Baseline | Men, n = 31 at Baseline | p* |
---|---|---|---|
Age at onset, yrs, mean ± SD | 45.9 ± 14.4 | 45.7 ± 14.8 | 0.93 |
Followup, yrs, mean ± SD | 13.1 ± 10.2 | 9.2 ± 6.9 | 0.046 |
Anti-Scl-70 positivity, % | 59.3 | 66.7 | 0.495 |
ACA positivity, % | 22.8 | 9.5 | 0.167 |
Diffuse skin involvement, % | 46.5 | 61.3 | 0.123 |
Pulmonary fibrosis, % | |||
1st–3rd year | 40.7 | 45.5 | 0.676 |
4th–6th year | 51.6 | 56.2 | 0.732 |
7th–9th year | 60.7 | 75.0 | 0.435 |
Upper GI tract, % | |||
1st–3rd year | 42.9 | 45.5 | 0.823 |
4th–6th year | 52.4 | 37.5 | 0.274 |
7th–9th year | 61.5 | 33.3 | 0.184 |
Lower GI tract, % | |||
1st–3rd year | 12.9 | 13.0 | 0.982 |
4th–6th year | 17.5 | 11.8 | 0.564 |
7th–9th year | 24.1 | 14.3 | 0.562 |
Contractures, % | |||
1st–3rd year | 10.8 | 33.3 | 0.019 |
4th–6th year | 15.5 | 37.5 | 0.122 |
7th–9th year | 31.1 | 66.7 | 0.206 |
LVEF ≤ 60% by ultrasound, % | |||
1st–3rd year | 13.0 | 20.0 | 0.373 |
4th–6th year | 15.2 | 16.7 | 0.875 |
7th–9th year | 15.8 | 18.2 | 0.850 |
PASP ≥ 40 mm Hg by ultrasound, % | |||
1st–3rd year | 12.6 | 18.2 | 0.495 |
4th–6th year | 19.7 | 20.0 | 0.981 |
7th–9th year | 34.1 | 33.3 | 0.971 |
Arrhythmia, % | |||
1st–3rd year | 17.0 | 26.3 | 0.342 |
4th–6th year | 23.7 | 18.2 | 0.685 |
7th–9th year | 31.7 | 20.0 | 0.591 |
Digital ulcers, % | |||
1st–3rd year | 31.5 | 54.2 | 0.036 |
4th–6th year | 37.5 | 56.2 | 0.163 |
7th–9th year | 58.5 | 50.0 | 0.651 |
Renal crisis, % | |||
1st–3rd year | 2.9 | 17.4 | 0.006 |
4th–6th year | 3.8 | 6.2 | 0.648 |
7th–9th year | 2.1 | 0 | 0.718 |
Numbers in bold type are statistically significant.
↵* By t-test for quantitative variables; by chi-squared for qualitative variables. ACA: anticentromere antibodies; GI: gastrointestinal; PASP: pulmonary arterial systolic pressure; LVEF: left ventricular ejection fraction.